Takeda, Ovid expand TAK-935 collaboration with three new trials

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (NASDAQ:OVID) expanded their collaboration for TAK-935 (OV935) to include three new trials in pediatric populations, including in two additional rare epilepsy syndromes. The partners expect to begin the trials this quarter.

Takeda and Ovid will conduct the Phase II ARCADE trial in about 30 pediatric patients ages 2 to 17 with cyclin dependent kinase like 5 (CDKL5) deficiency disorder or duplication 15q syndrome and the Phase II ELEKTRA trial in pediatric patients ages 2 to 17 with Dravet syndrome or Lennox-Gastaut syndrome (LGS)...